Capsule Summaries From EASL

[Guest guest]

INDEPENDENT CONFERENCE COVERAGE 2011 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

CLICK TO ACCESSConference Coverage From Berlin, Germany

CCO's Independent Conference Coverage of EASL 2011 in Berlin, Germany, includes Capsule Summaries of the most clinically relevant data presented at the meeting, an original CCO highlights slideset, and a CME-certified Expert Analysis.

To browse available coverage, click here or select a link below.

Capsule Summaries:Capsule Summaries are “quick read†reviews of key oral and poster presentations, handpicked by leading experts in hepatology. The comprehensive contents are based on the actual data presented at the meeting—providing the most up-to-date information.

CLICK TO ACCESSFrom Podium to Practice: Clinical Impact of New Data From EASL 2011Click a link below to access Capsule Summaries

REALIZE Subanalysis: IL28B Genotype Not Significantly Associated With SVR in Treatment-Experienced Patients Receiving Telaprevir-Based Triple Therapy for HCV Infection – Link

IL28B Genotype Predicts Lead-in Response, Likelihood of Shortened Therapy in SPRINT-2 and RESPOND-2 Phase III Boceprevir Trials – Link

SILEN-C1: High Rate of Rapid and Sustained Virologic Response With Addition of BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV Infection – Link

Ritonavir-Boosted Danoprevir Plus PegIFN/RBV Produces Potent Antiviral Activity in Null Responders Infected With Genotype 1b HCV but High Rate of Viral Breakthrough With Genotype 1a – Link

In Previous Null Responders With Genotype 1 HCV Infection, BMS-790052 Plus BMS-650032 Produces SVR in 36% Receiving Dual Therapy, 100% Receiving Concomitant PegIFN/RBV – Link

ZENITH Interim Results: Potent Antiviral Activity With 12 Weeks of VX-222 + Telaprevir + PegIFN/RBV Quad Therapy, but Virologic Breakthrough Common With VX-222 + Telaprevir Dual Therapy – Link

IL28B Genotype May Predict Response to PegIFN Treatment in Patients Chronically Infected With HBeAg-Positive Hepatitis B – Link

Biochemical and Histopathologic Outcomes Not Improved With Addition of Metformin or Losartan to Rosiglitazone vs Rosiglitazone Alone in Patients With NASH – Link

SOCRATES: Combining Sorafenib and TACE for Treatment of Advanced Hepatocellular Carcinoma Yields Promising Efficacy Results – Link

This Conference Coverage is located online at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Coming Soon: CME-Certified Expert Analysis

2011 Annual Meeting of the European Association for the Study of the LiverLeading experts discuss the most clinically relevant data from the meeting in Berlin, Germany, in a CME-certified Expert Analysis.

This program is located online at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb; Pharmasset, Inc.; and Vertex.

Clinical Care Options Hepatitis

GET MORE FROM CCO2011 Annual CCO HIV and Hepatitis C Symposium

Register today for the 2011 Annual CCO HIV and Hepatitis C Symposium for a review of the most important scientific and clinical advances over the past year, including expert guidance on integrating novel HCV agents into clinical care. Click here for more information.

Conference CoverageJournal OptionsManagement SeriesTreatment UpdatesInteractive Cases

Live MeetingsRSS / PodcastsMy CME TrackerFree BookstoreSlide

Downloads

Clinical Care Options, LLC. 1894 Preston White Drive, Suite 110, Reston, VA 20191-5433

To ensure you receive Clinical Care Options educational materials by email,please add info@... to your contacts or address book.

Not a member yet? Click here